CNBX Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Year Ending	TTM	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020	Aug 31, 2019	2018 - 2013
Net Income	-1.21	-3.71	-3.72	-3.19	-7.47	1.13	Upgrade
Depreciation & Amortization	0.11	0.16	0.2	0.22	0.22	0.19	Upgrade
Loss (Gain) From Sale of Investments	0.42	2.73	-0.01	-0.2	-0.11	-0.14	Upgrade
Stock-Based Compensation	0.14	0.18	0.73	0.03	0.07	0.25	Upgrade
Other Operating Activities	0.06	0.05	0.72	0.71	4.36	-4.36	Upgrade
Change in Accounts Receivable	0.3	-0.01	0.12	-0.01	0.13	-0.06	Upgrade
Change in Accounts Payable	0	0.49	0.28	-0.05	0.02	-0.1	Upgrade
Operating Cash Flow	-0.18	-0.11	-1.68	-2.49	-2.77	-3.09	Upgrade
Capital Expenditures	-0	-	-0	-0	-0.08	-0.22	Upgrade
Sale of Property, Plant & Equipment	0.11	-	0.03	-	-	-	Upgrade
Investment in Securities	-	0.02	-	0.65	3.36	-5.03	Upgrade
Investing Cash Flow	0.11	0.02	0.03	0.65	3.29	-5.25	Upgrade
Short-Term Debt Issued	-	0.1	0.39	2.46	-	-	Upgrade
Total Debt Issued	0.09	0.1	0.39	2.46	-	-	Upgrade
Net Debt Issued (Repaid)	0.09	0.1	0.39	2.46	-	-	Upgrade
Issuance of Common Stock	-	-	-	-	-	7.29	Upgrade
Other Financing Activities	-	-	-	-	-	-0.08	Upgrade
Financing Cash Flow	0.09	0.1	0.39	2.46	-	7.22	Upgrade
Foreign Exchange Rate Adjustments	-	-	-0	-	-	-	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	-	-	0	Upgrade
Net Cash Flow	0.03	0.01	-1.27	0.61	0.51	-1.13	Upgrade
Free Cash Flow	-0.18	-0.11	-1.68	-2.49	-2.85	-3.31	Upgrade
Free Cash Flow Margin	-76.80%	-27.43%	-5610.68%	-	-39830.98%	-33634.70%	Upgrade
Free Cash Flow Per Share	-0.01	-0.01	-1.37	-2.16	-2.54	-3.00	Upgrade
Levered Free Cash Flow	0.09	0.23	-0.51	-1.48	-1.05	-2.51	Upgrade
Unlevered Free Cash Flow	0.12	0.23	-0.51	-1.48	-1.04	-2.5	Upgrade
Change in Net Working Capital	-0.3	-0.47	-0.41	0.11	-0.65	0.66	Upgrade

Source: S&P Capital IQ. Standard template.